Trial NCT02846792

View at ClinicalTrials.gov 
Org. Study IDs: 9602
Secondary IDs: 9602 NCI-2016-01009 P30CA015704

Last trial update was posted on 2019-03-04

MeSH Interventions

Nivolumab

MeSH Conditions

Carcinoma, Non-Small-Cell Lung Lung Neoplasms

Other Conditions

ALK Gene Translocation EGFR Activating Mutation ROS1 Gene Translocation Recurrent Non-Small Cell Lung Carcinoma Stage IIIB Non-Small Cell Lung Cancer AJCC v7 Stage IV Non-Small Cell Lung Cancer AJCC v7

Stopping Reasons

Immunotherapy approved for NSCLC in the first line setting

Limitations And Caveats

Study terminated (stopped prematurely), due to immunotherapy approved for NSCLC in the first line setting. Participant flow, Baseline Characteristics and Adverse Events recorded for 5 patients treated on study.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID